Membrane transporters in drug development
Open accessThe DOI matches its Crossref record; 225 of the 225 references it cites were found in a registry or an index.
Abstract
Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clinical studies on the currently recognized most important drug transporter interactions. The recommendations are generally intended to support clinical development and filing of a new drug application. Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, the human genome has been proven to have more than 400 membrane transporters, which are divided into two families: ATP binding cassette (ABC) and solute carrier (SLC) transporters [114].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Self-citationMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Cited by
Items 601–700 of 1,008
Structural basis for prodrug recognition by the SLC15 family of proton-coupled peptide transporters
Minhas, G. S., & Newstead, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813715116 · Cited by 60
de Klerk, D. J., Honeywell, R. J., Jansen, G., & Peters, G. J. (2018) · Cancers · doi:10.3390/cancers10120503 · Cited by 64
Scotcher, D., Jones, C., Rostami-Hodjegan, A., & Galetin, A. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.018 · Cited by 61
Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives
Zou, L., Spanogiannopoulos, P., Pieper, L. M., Chien, H.-C., Cai, W., Khuri, N., Pottel, J., Vora, B., Ni, Z., Tsakalozou, E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920483117 · Cited by 61
Self-citationStrategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes
Pfefferkorn, J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.748744 · Cited by 56
Defining and characterizing drug/compound function
Kenakin, T., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.033 · Cited by 69
Chen, E. C., Broccatelli, F., Plise, E. G., Chen, B., Liu, L., Cheong, J., Zhang, S., Jorski, J., Gaffney, K., Umemoto, K. K., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00688 · Cited by 61
Zamek‐Gliszczynski, M. J., Sangha, V., Shen, H., Feng, B., Wittwer, M., Varma, M. V. S., Liang, X., Sugiyama, Y., Zhang, L., & Bendayan, R. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2644 · Cited by 61
Self-citationMak, L., Marcus, D., Howlett, A., Yarova, G., Duchateau, G. S. M. J. E., Klaffke, W., Bender, A., & Glen, R. C. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0083-5 · Cited by 61
Psychotropic Drug–Drug Interactions Involving P-Glycoprotein
Akamine, Y., Yasui‐Furukori, N., Ieiri, I., & Uno, T. (2012) · CNS Drugs · doi:10.1007/s40263-012-0008-z · Cited by 66
Gunn, R. N., Summerfield, S. G., Salinas, C. A., Read, K. D., Guo, Q., Searle, G. E., Parker, C. A., Jeffrey, P., & Laruelle, M. A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.1 · Cited by 62
Kikuchi, R., Lao, Y., Bow, D. A. J., Chiou, W. J. H., Andracki, M. E., Carr, R. A., Voorman, R. L., & de Morais, S. M. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23737 · Cited by 61
Establishment of Optimized MDCK Cell Lines for Reliable Efflux Transport Studies
Gartzke, D., & Fricker, G. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23901 · Cited by 61
Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Liu, J. J., Lu, J., & McKeage, M. J. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912803251199 · Cited by 68
Chu, X., Shih, S., Shaw, R. J., Hentze, H., Chan, G. H., Owens, K. A., Wang, S., Cai, X., Newton, D. J., Castro‐Perez, J. M., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063347 · Cited by 64
Self-citationExpression and Transport Function of Drug Uptake Transporters in Differentiated HepaRG Cells
Kotani, N., Maeda, K., Debori, Y., Camus, S., Li, R., Chesné, C., & Sugiyama, Y. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300171p · Cited by 61
Self-citationOlthof, P. B., van Golen, R. F., Meijer, B., van Beek, A. A., Bennink, R. J., Verheij, J., van Gulik, T. M., & Heger, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.10.022 · Cited by 65
Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib
Posada, M. M., Cannady, E. A., Payne, C. D., Zhang, X., Bacon, J. A., Pak, Y. A., Higgins, J. W., Shahri, N., Hall, S. D., & Hillgren, K. M. (2017) · Clinical and Translational Science · doi:10.1111/cts.12486 · Cited by 61
Self-citationPharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation
Tron, C., Lemaitre, F., Verstuyft, C., Petitcollin, A., Verdier, M., & Bellissant, É. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0717-7 · Cited by 61
Teng, Y., Wang, C. C. N., Liao, W.-C., Lan, Y., & Hung, C. (2020) · Molecules · doi:10.3390/molecules25020247 · Cited by 63
Coordinating the impact of structural genomics on the human α-helical transmembrane proteome
Pieper, U., Schlessinger, A., Kloppmann, E., Chang, G. A., Chou, J. J., Dumont, M. E., Fox, B. G., Fromme, P., Hendrickson, W. A., Malkowski, M. G., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2508 · Cited by 61
Bruyn, T. D., Ye, Z., Peeters, A., Sahi, J., Baes, M. I., Augustijns, P., & Annaert, P. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.05.002 · Cited by 60
Zhao, H., Huang, Y., Shi, J., Dai, Y., Wu, L., & Zhou, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01312 · Cited by 62
Mechanisms of Polymyxin-Induced Nephrotoxicity
Azad, M. A. K., Nation, R. L., Velkov, T., & Li, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16373-0_18 · Cited by 60
Sudhakaran, M., Parra, M. R., Stoub, H., Gallo, K. A., & Doseff, A. I. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114259 · Cited by 60
Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport
Elz, A. S., Trevaskis, N. L., Porter, C. J. H., Bowen, J. M., & Prestidge, C. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.003 · Cited by 64
Agarwal, S., Arya, V., & Zhang, L. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011436344 · Cited by 60
Self-citationStott, L. C., Schnell, S., Högstrand, C., Owen, S. F., & Bury, N. R. (2014) · Aquatic Toxicology · doi:10.1016/j.aquatox.2014.12.007 · Cited by 60
Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2
Eechoute, K., Franke, R. M., Loos, W. J., Scherkenbach, L. A., Boere, I., Verweij, J., Gurney, H., Kim, R. B., Tirona, R. G., Mathijssen, R. H. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.42 · Cited by 60
Self-citationLenhart, J. A., Ling, X., Gandhi, R., Guo, T. L., Gerk, P. M., Brunzell, D. H., & Zhang, S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100601q · Cited by 60
The right compound in the right assay at the right time: an integrated discovery DMPK strategy
Ballard, P. G., Brassil, P. J., Bui, K., Dolgos, H., Petersson, C., Tunek, A., & Webborn, P. J. H. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.691099 · Cited by 64
Lipid outward translocation by ABC proteins
Nagao, K., Kimura, Y., Mastuo, M., & Ueda, K. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.036 · Cited by 59
Oswald, S., Gröer, C., Droździk, M., & Siegmund, W. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9521-3 · Cited by 62
Varma, M. V. S., Lin, J., Bi, Y., Rotter, C. J., Fahmi, O. A., Lam, J. L., El‐Kattan, A. F., Goosen, T. C., & Lai, Y. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050583 · Cited by 62
Russell, M. R., Achour, B., McKenzie, E. A., Lopez, R., Harwood, M. D., Rostami‐Hodjegan, A., & Barber, J. (2013) · Journal of Proteome Research · doi:10.1021/pr400279u · Cited by 60
Imamura, Y., Tsuruya, Y., Damme, K., Heer, D., Kumagai, Y., Maeda, K., Murayama, N., Okudaira, N., Kurihara, A., Izumi, T., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.055475 · Cited by 60
Self-citationIdentification of OAT1/OAT3 as Contributors to Cisplatin Toxicity
Hu, S., Leblanc, A. F., Gibson, A., Hong, K., Kim, J., Janke, L. J., Li, L., Vasilyeva, A. N., Finkelstein, D., Sprowl, J. A., et al. (2017) · Clinical and Translational Science · doi:10.1111/cts.12480 · Cited by 60
Oswald, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.007 · Cited by 66
Advances and Challenges in Rational Drug Design for SLCs
Garibsingh, R. A., & Schlessinger, A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.08.006 · Cited by 66
Li, T., An, J., Xu, J., & Tuo, B. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i23.3915 · Cited by 67
Anderson, L. L., Etchart, M. G., Bahceci, D., Golembiewski, T. A., & Arnold, J. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-94212-6 · Cited by 63
Nanoparticle oral absorption and its clinical translational potential
Kim, K. S., Na, K., & Bae, Y. H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.024 · Cited by 60
Keuper-Navis, M., Walles, M., Poller, B., Myszczyszyn, A., van der Made, T. K., Donkers, J., Eslami Amirabadi, H., Wilmer, M. J., Aan, S., Spee, B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106853 · Cited by 52
Rasool, M. F., Khalil, F., & Läer, S. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0253-7 · Cited by 55
Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib
Traxl, A., Wanek, T., Mairinger, S., Stanek, J., Filip, T., Sauberer, M., Müller, M., Kuntner, C., & Langer, O. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161273 · Cited by 59
Molecular Insight into Affinities of Drugs and Their Metabolites to Lipid Bilayers
Paloncýová, M., Berka, K., & Otyepka, M. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp311802x · Cited by 59
Ozawa, T., Takayama, K., Okamoto, R., Negoro, R., Sakurai, F., Tachibana, M., Kawabata, K., & Mizuguchi, H. (2015) · Scientific Reports · doi:10.1038/srep16479 · Cited by 59
Patik, I., Székely, V., Német, O., Szepesi, Á., Kucsma, N., Várady, G., Szakács, G., Bakos, É., & Özvegy‐Laczka, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-20815-1 · Cited by 60
New Human Organotypic Corneal Tissue Model for Ophthalmic Drug Delivery Studies
Kaluzhny, Y., Kinuthia, M. W., Truong, T., Lapointe, A. M., Hayden, P. J., & Klausner, M. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-23944 · Cited by 61
Kell, D. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.10.005 · Cited by 58
Ryu, S., Yamaguchi, E., Modaresi, S. M. S., Agudelo, J., Costales, C., West, M. A., Fischer, F. C., & Slitt, A. L. (2024) · Chemosphere · doi:10.1016/j.chemosphere.2024.142390 · Cited by 59
Active Sulforhodamine 101 Uptake into Hippocampal Astrocytes
Schnell, C., Hagos, Y., & Hülsmann, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049398 · Cited by 55
An integrated pharmacokinetics ontology and corpus for text mining
Wu, H., Karnik, S., Subhadarshini, A., Wang, Z. P., Philips, S., Han, X., Chiang, C., Liu, L., Boustani, M. A., Rocha, L. M., et al. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-35 · Cited by 58
Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
Sidharta, P. N., Treiber, A., & Dingemanse, J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0255-5 · Cited by 60
Krishnaswami, S., Chow, V., Boy, M. G., Wang, C., & Chan, G. L. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.178 · Cited by 58
Nicol, M. R., Fedoriw, Y. D., Mathews, M. M., Prince, H. M. A., Patterson, K. B., Geller, E. J., Mollan, K. R., Mathews, S. P., Kroetz, D. L., & Kashuba, A. D. M. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.248 · Cited by 58
Rafaniello, C., Sessa, M., Bernardi, F. F., Pozzi, M., Cheli, S., Cattaneo, D., Baldelli, S., Molteni, M., Bernardini, R., Rossi, F., et al. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.38 · Cited by 58
Hodin, S., Basset, T., Jacqueroux, E., Delézay, O., Clotagatide, A., Perek, N., Mismetti, P., & Delavenne, X. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0434-x · Cited by 58
Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography
Bauer, M., Matsuda, A., Wulkersdorfer, B., Philippe, C., Traxl, A., Özvegy‐Laczka, C., Stanek, J., Nics, L., Klebermass, E., Poschner, S., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.888 · Cited by 58
Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine
Meyer, M. J., Seitz, T., Brockmöller, J., & Tzvetkov, M. V. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189521 · Cited by 57
Al-Ali, A. A. A., Nielsen, R. B., Steffansen, B., Holm, R., & Nielsen, C. U. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.033 · Cited by 61
Herbert, F. C., Abeyrathna, S., Abeyrathna, N. S., Wijesundara, Y. H., Brohlin, O. R., Carraro, F., Amenitsch, H. W., Falcaro, P., Luzuriaga, M. A., Durand-Silva, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22285-y · Cited by 59
Oligomeric bile acid-mediated oral delivery of low molecular weight heparin
Al-Hilal, T. A., Park, J., Alam, F., Chung, S. W., Park, J. W., Kim, K., Kwon, I. C., Kim, I.-S., Kim, S. Y., & Byun, Y. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.12.001 · Cited by 57
In vivo imaging of drug delivery systems in the gastrointestinal tract
Weitschies, W., & WILSON, C. G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.031 · Cited by 62
Tamraz, B., Fukushima, H., Wolfe, A. R., Kaspera, R., Totah, R. A., Floyd, J. S., Ma, B., Chu, C., Marciante, K. D., Heckbert, S. R., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283620c3b · Cited by 67
Ni, W., Ji, J., Dai, Z., Papp, A. C., Johnson, A. J., Ahn, S., Farley, K. L., Lin, T. S., Dalton, J. T., Li, X., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013792 · Cited by 57
Zolnerciks, J. K., Booth-Genthe, C. L., Gupta, A., Harris, J. J., & Unadkat, J. D. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22566 · Cited by 57
Gong, I. Y., Mansell, S. E., & Kim, R. B. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12005 · Cited by 57
Self-citationHazai, E., Hazai, I., Ragueneau, I., Chung, S. P., Bikádi, Z., & Mao, Q. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-130 · Cited by 62
Pharmacogenomics in Early-Phase Clinical Development
Burt, T., & Dhillon, S. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.81 · Cited by 57
Peng, K., Bacon, J. A., Zheng, M., Guo, Y., & Wang, M. Z. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063362 · Cited by 61
Renal drug–drug interactions: what we have learned and where we are going
Lepist, E., & Ray, A. S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.667401 · Cited by 57
Chu, X., Cai, X., Cui, D., Tang, C., Ghosal, A., Chan, G. H., Green, M. D., Kuo, Y., Liang, Y., Maciolek, C. M., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.049668 · Cited by 61
Self-citationUse of PET Imaging to Evaluate Transporter‐Mediated Drug‐Drug Interactions
Langer, O. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.722 · Cited by 56
Cocucci, E., Kim, J., Bai, Y., & Pabla, N. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.545 · Cited by 57
Sorf, A., Hofman, J., Kučera, R., Štaud, F., & Čečková, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.04.013 · Cited by 58
Bagal, S. K., Omoto, K., Blakemore, D. C., Bungay, P. J., Bilsland, J., Clarke, P. J., Corbett, M. S., Cronin, C. N., Cui, J. J., Dias, R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00280 · Cited by 57
Kimoto, E., Mathialagan, S., Tylaska, L. A., Niosi, M., Lin, J., Carlo, A. A., Tess, D. A., & Varma, M. V. S. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.252049 · Cited by 58
Drug–Exposome Interactions: The Next Frontier in Precision Medicine
Pristner, M., & Warth, B. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.012 · Cited by 61
Markus, J., Landry, T., Stevens, Z., Scott, H., Llanos, P., Debatis, M. E., Armento, A. J., Klausner, M., & Ayehunie, S. (2020) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-020-00526-6 · Cited by 57
Renal Transport of Organic Anions and Cations
Pelis, R. M., & Wright, S. H. (2011) · Comprehensive physiology · doi:10.1002/cphy.c100084 · Cited by 58
Self-citationOrganic cation transporter-mediated drug-drug interaction potential between berberine and metformin
Kwon, M., Choi, Y. A., Choi, M.-K., & Song, I.-S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0510-6 · Cited by 56
Tchaparian, E. H., Houghton, J. S., Uyeda, C., Grillo, M. P., & Jin, L. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039545 · Cited by 64
The Structure and Mechanism of Drug Transporters
Roberts, A. G. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1554-6_8 · Cited by 66
Oral Anticoagulants Beyond Warfarin
Olie, R. H., Winckers, K., Rocca, B., & Cate, H. T. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032823-122811 · Cited by 63
The potential of immobilized artificial membrane chromatography to predict human oral absorption
Tsopelas, F. N., Vallianatou, T., & Tsantili‐Kakoulidou, A. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.09.020 · Cited by 56
Reis, J. M., Dezani, A. B., Pereira, T. M., Avdeef, A., & Serra, C. H. R. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.025 · Cited by 56
Emoto, C., Fukuda, T., Cox, S., Christians, U., & Vinks, A. A. T. M. M. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.33 · Cited by 57
Ferreira, A., Pousinho, S., Fortuna, A. C., Falcão, A. C., & Alves, G. (2014) · Phytochemistry Reviews · doi:10.1007/s11101-014-9358-0 · Cited by 60
Expression of Efflux Transporters in Human Ocular Tissues
Chen, P., Chen, H., Zang, X., Chen, M., Jiang, H., Han, S., & Wu, X. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052704 · Cited by 56
Models to Predict Unbound Intracellular Drug Concentrations in the Presence of Transporters
Korzekwa, K., Nagar, S., Tucker, J., Weiskircher-Hildebrandt, E. A., Bhoopathy, S., & Hidalgo, I. J. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.044289 · Cited by 60
Molecular Dissection of Dual Pseudosymmetric Solute Translocation Pathways in Human P-Glycoprotein
Parveen, Z., Stockner, T., Bentele, C., Pferschy, S., Kraupp, M., Freissmuth, M., Ecker, G. F., & Chiba, P. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067611 · Cited by 56
The effects of dietary and herbal phytochemicals on drug transporters
Li, Y., Revalde, J. L., & Paxton, J. W. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.09.004 · Cited by 60
Mathialagan, S., Rodrigues, A. D., & Feng, B. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.009 · Cited by 56
Bowman, C. M., Okochi, H., & Benet, L. Z. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.085779 · Cited by 60
Self-citationKhunweeraphong, N., & Kuchler, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094806 · Cited by 53
Interaction of Silymarin Flavonolignans with Organic Anion-Transporting Polypeptides
Köck, K., Xie, Y., Hawke, R. L., Oberlies, N. H., & Brouwer, K. L. R. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048272 · Cited by 56
Self-citationMcRobb, F. M., Sahagún, V., Kufareva, I., & Abagyan, R. (2014) · Environmental Science & Technology · doi:10.1021/es404568a · Cited by 55
Single compartment drug delivery
Cima, M. J., Lee, H., Daniel, K. D., Tanenbaum, L. M., Mantzavinou, A., Spencer, K. C., Ong, Q., Sy, J. C., Santini, J. T., Schoellhammer, C. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.049 · Cited by 60
Li, Y., & Paxton, J. W. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.749858 · Cited by 60
Metadata
- Authors
- The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K. M., Hoffmaster, K. A., Ishikawa, T., Keppler, D., Kim, R. B., Lee, C. A., Niemi, M., Polli, J. W., Sugiyama, Y., Swaan, P. W., Ware, J. A., Wright, S. H., Wah Yee, S., Zamek-Gliszczynski, M. J., & Zhang, L.
- Affiliations
- University of California, San Francisco (US)
- United States Food and Drug Administration (US)
- Boehringer Ingelheim (United States) (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Abbott (United States) (US)
- Eli Lilly (United States) (US)
- Novartis (United States) (US)
- RIKEN (JP)
- German Cancer Research Center (DE)
- Western University (CA)
- GlaxoSmithKline (United Kingdom) (GB)
- Genentech (US)
- University of Maryland, Baltimore (US)
- University of Arizona (US)
- ORCID
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-03
- Volume
- 9
- Issue
- 3
- Pages
- 215-236
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3326076
- OpenAlex
- W2079197876
- Cited by
- 3,340
- References
- 225
- Citations by year
- 2026: 105 · 2025: 118 · 2024: 153 · 2023: 175 · 2022: 180 · 2021: 237 · 2020: 187 · 2019: 219 · 2018: 234 · 2017: 216 · 2016: 242 · 2015: 233 · 2014: 248 · 2013: 316 · 2012: 254
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Funders
- National Institutes of Health (GM61390)
- U.S. Food and Drug Administration
- National Institute of General Medical Sciences (GM61390, R01GM041935, U19GM061390, U01GM061390)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080801, R01DK061425)
- National Institute of Environmental Health Sciences (P30ES006694)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- membrane transporters, drug transporters, drug-drug interactions, pharmacokinetics, drug absorption, drug disposition, drug development, drug safety and efficacy, drug labeling
- MeSH terms
- Animals, Computer Simulation, Decision Trees, Drug Interactions, Drug Evaluation, Preclinical, Humans, Drug Approval, Mice, Knockout, Membrane Transport Proteins, Mice, Prescription Drugs, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.